- Home
- MGIH vs BIVI Comparison
MGIH vs BIVI Comparison
Compare MGIH & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- BIVI
- Stock Information
- Founded
- MGIH 1978
- BIVI 2013
- Country
- MGIH Hong Kong
- BIVI United States
- Employees
- MGIH N/A
- BIVI N/A
- Industry
- MGIH Publishing
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- BIVI Health Care
- Exchange
- MGIH Nasdaq
- BIVI Nasdaq
- Market Cap
- MGIH 17.3M
- BIVI 18.6M
- IPO Year
- MGIH 2023
- BIVI N/A
- Fundamental
- Price
- MGIH $1.58
- BIVI $0.97
- Analyst Decision
- MGIH
- BIVI Strong Buy
- Analyst Count
- MGIH 0
- BIVI 1
- Target Price
- MGIH N/A
- BIVI $30.00
- AVG Volume (30 Days)
- MGIH 11.1K
- BIVI 208.2K
- Earning Date
- MGIH 07-07-2025
- BIVI 05-12-2025
- Dividend Yield
- MGIH N/A
- BIVI N/A
- EPS Growth
- MGIH N/A
- BIVI N/A
- EPS
- MGIH N/A
- BIVI N/A
- Revenue
- MGIH $28,866,993.00
- BIVI N/A
- Revenue This Year
- MGIH N/A
- BIVI N/A
- Revenue Next Year
- MGIH N/A
- BIVI N/A
- P/E Ratio
- MGIH N/A
- BIVI N/A
- Revenue Growth
- MGIH N/A
- BIVI N/A
- 52 Week Low
- MGIH $1.32
- BIVI $0.62
- 52 Week High
- MGIH $6.83
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- MGIH 48.50
- BIVI 43.61
- Support Level
- MGIH $1.56
- BIVI $0.88
- Resistance Level
- MGIH $1.67
- BIVI $1.07
- Average True Range (ATR)
- MGIH 0.09
- BIVI 0.08
- MACD
- MGIH -0.01
- BIVI -0.02
- Stochastic Oscillator
- MGIH 32.84
- BIVI 27.39
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.